Hyaluronic acid as a treatment for ankle osteoarthritis

Abstract

Viscosupplementation refers to the concept of synovial fluid replacement with intra-articular injections of hyaluronic acid (HA) for the relief of pain associated with osteoarthritis (OA). Intra-articular viscosupplementation was approved by the Food and Drug Administration (FDA) in 1997. It is currently indicated only for the treatment of pain associated with knee OA. However, OA can occur in several of the weight-bearing joints of the foot and ankle. Ankle OA produces chronic disability that directly impacts the quality of life. There is only limited published literature relating to the use of HA in the ankle. This paper will review the authors’ experience, indications, clinical outcomes, and complications of viscosupplementation therapy in patients with ankle OA.

I.S.Mu.L.T. Hyaluronic acid injections in musculoskeletal disorders guidelines

“…Many methods of treatment have been proposed, but actually no precise algorithm has been defined. HA is typically used when first-level analgesics have not determined adequate benefit and it could represent an option to postpone surgery 121,122 . In selected studies (7 studies; 5 RCTs) response to treat-…”

Schwann-cell cylinders grown inside hyaluronic-acid tubular scaffolds with gradient porosity

“…However, once reacted with the OH groups of the HA molecule these double bonds disappear, and, if non-reacted molecules are thoroughly removed, the resulting HA-DVS networks are devoid of inflammatory, pyrogenic or cytotoxic effects [47][48][49][50]. HA-based materials employed in clinic for several uses in humans contain HA-DVS networks and count with FDA approval [51,52].…”

Applications and emerging trends of hyaluronic acid in tissue engineering, as a dermal filler and in osteoarthritis treatment

“…Currently, several viscosupplements including Hyalgan®, Supartz®, Orthovisc®, Synvisc®, and Euflexxa® are available on the market. Each of these products differ in their method of production, molecular weight, dosing instructions, and possibly clinical outcomes [147]. …”